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ABSTRACT 
 
Driven by advancements in high-throughput biological technologies and the growing 
number of sequenced genomes, the construction of in silico models at the genome 
scale has provided powerful tools to investigate a vast array of biological systems and 
applications.  Here, we review comprehensively the uses of such models in industrial 
and medical biotechnology, including biofuel generation, food production, and drug 
development.  While the use of in silico models is still in its early stages for 
delivering to industry, significant initial successes have been achieved.  For the cases 
presented here, genome-scale models predict engineering strategies to enhance 
properties of interest in an organism or to inhibit harmful mechanisms of pathogens 
or in disease.  Going forward, genome-scale in silico models promise to extend their 
application and analysis scope to become a transformative tool in biotechnology.  As 
such, genome-scale models can provide a basis for rational genome-scale engineering 
and synthetic biology. 
 
1 INTRODUCTION & BACKGROUND 
 
Genome-scale in silico models provide a powerful resource to guide rational 
engineering of biological systems for applications in industrial and medical 
biotechnology.  An accurate genome-scale model (GEM) can help predict the 
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system-wide effect of genetic and environmental perturbations on an organism, and 
hence drive metabolic engineering experiments.  Since the development of the first 
GEM in 1999 (Haemophilus influenza [1]), systems modeling approaches have 
worked towards efficiently utilizing increasingly available high-throughput biological 
data (e.g., genomics, transcriptomics, proteomics, metabolomics) to bring genomes to 
life.  An important challenge in this field is to enable the rapid development of 
predictive computational models for any sequenced organism by harnessing these 
high-throughput experimental technologies.  The compelling need for this ability is 
evidenced by the gap between the number of sequenced organisms and corresponding 
GEMs (Figure 1).  
 
Three classes of networks have been reconstructed in biochemical detail and 
converted into GEMs.  Metabolic GEMs quantify a cell’s metabolic potential, and 
thus allow researchers to probe new phenotypes and network states [2].  
Transcriptional regulatory networks (TRNs) describe transcription-factor-
promoter interactions and associated environmental influences to provide information 
about environment-specific enzyme activity.  As such, TRNs can be fused with 
metabolic GEMs to form more predictive integrated metabolic-regulatory network 
models [3-6].  The newest genome-scale network type, transcriptional-translational 
models [7], captures information passage from DNA to RNA to proteins.  Each 
network-based GEM is built upon a stoichiometric formalism allowing for the 
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mathematical representation of biochemical information (see [2, 8-10]).  The present 
review focuses heavily on metabolic GEMs because they are the most commonly 
formulated and span a broad range of applications. 
 
Numerous constraint-based methods are available to explore the phenotypic potential 
of the three GEM types, and by extension the associated biological system.  To assist 
in understanding the case studies discussed  herein, we briefly summarize some of 
these procedures (see [11] for review).  In constraint-based analysis, physico-
chemical and environmental constraints are applied as balances (e.g., mass, energy) 
and bounds (e.g., flux capacities, thermodynamics).  These constraints define a 
solution space describing all possible functions (allowable phenotypes) of the system.  
Flux balance analysis (FBA) determines the distribution of reaction fluxes that 
optimize a biological objective function (e.g., biomass, ATP) [12, 13].  This 
capability is particularly useful for simulating the effect of genetic perturbations (e.g., 
gene knockouts or mutations) on the resulting metabolic phenotype.  Two extensions 
of traditional FBA, regulatory FBA (rFBA) [3, 6] and dynamic FBA (dFBA) [14],  
enable analysis and hypothesis generation where external metabolite concentrations 
and environmental conditions vary with time.  Minimization of metabolic 
adjustment (MOMA) assumes that, after a mutation, the organism seeks to 
minimize the total metabolic change relative to the wildtype (unlike FBA, which 
assumes a new optimized network state) [15]. OptKnock [16] is a computational 
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procedure used to design strains with enhanced capabilities by identifying gene 
deletions that align the cellular objective (e.g., growth) with the engineering objective 
(e.g., biofuel production).  The effects of gene additions from related organisms can 
be  included in an analogous fashion using OptStrain [17]. 
 
This review provides detailed examples of how constraint-based GEM analysis has 
been used for a broad range of applications in industrial and medical biotechnology 
(Figure 2).  To date, there are over 50 organism-specific GEMs (Table 1) that have 
been surprisingly successful in predicting cellular behavior (e.g., the effects of gene 
deletions on growth or secretion rates).  In biotechnology applications, GEMs are 
commonly used to guide enhancement of a particular property of interest (e.g., 
biofuel or pharmaceutical production) or to better understand systemic behavior.  
Hence, two specific uses for GEMs are addressed: (i) elucidation of the global 
properties of network structures and (ii) constraint-based modeling for predicting the 
phenotypic effects of genetic and environmental perturbations.   
 
2 INDUSTRIAL BIOTECHNOLOGY APPLICATIONS OF GENOME-SCALE 
IN SILICO METABOLIC MODELS  
 
Metabolic GEMs provide a valuable tool to harness microorganisms as cell factories 
to sustainably produce chemicals and pharmaceuticals.  The ability to integrate 
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targeted modifications within the context of the whole organism helps model-guided 
approaches to minimize undesired secondary effects.  An iterative model generation, 
hypothesis formation, and model refinement process is central to the systems biology 
approach (Figure 3).  Current metabolic GEMs for industrial biotechnology fall into 
four main application categories: food production, biopolymers, biofuels, and 
bioremediation.   
 
2.1 Food Production and Engineering 
 
In the food and beverage industry, metabolic GEMs have been created to explore and 
improve fermentation byproduct formation by lactic acid bacteria (LAB).  In addition 
to lactate, LAB produce bacteriocins, exopolysaccharides, polyols, B vitamins and 
compounds that affect food texture, taste, and preservation [18].   
 
Lactobacillus plantarum is used in industrial food fermentations and advertized as a 
probiotic organism.  FBA was used to compare the typical estimation method for 
ATP production (based on lactate and acetate formation) to that predicted by the 
metabolic GEM, and was found to match.  The accuracy of the acid-formation based 
method had been questioned because some inputs to lactate and acetate formation do 
not yield ATP. During the ATP production analysis, it was discovered that 
transamination of aromatic and branched chain amino acids contributes to ATP 
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production.  A second investigation with the GEM investigated the discrepancy 
between experimental and FBA predicted growth rates and lactate formation. FBA 
predicted mixed acid production (primarily acetate, ethanol, formate) when optimized 
for growth, while homolactic fermentation is observed experimentally.  Additionally, 
the FBA-predicted growth rate was higher than expected. These differences were 
thought to result from the experimental observation that L. plantarum uses an ATP 
inefficient route for lactate production, and thus does not maximize ATP production 
as its cellular objective (the FBA assumption used) – likely stemming from its 
evolution in nutrient-rich environments.   This observation was investigated further in 
a study that evolved an experimental strain for growth on glycerol  [19].  The poor 
substrate expectedly forced the strain into optimization for growth, producing mainly 
lactate with an experimental growth rate of 0.26h-1, compared to 0.324h-1 found in 
silico.  Thus, the experimental mutant developed to follow traditional FBA 
assumptions agreed better with in silico predictions.  
 
In addition to typical LAB production applications in the food industry, Lactococcus 
lactis has applications relating to the in situ production of flavor, texture and health 
contributing food components.  The GEM for L. lactis was used to predict 
modifications for enhanced production of diacetyl, a flavor compound in dairy 
products [20].  FBA and MOMA were used to optimize for production of the 
intermediate 2-acetolactate.  In silico predictions starting with a known mutant strain 
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yielded an additional deletion for increased acetate formation.  In a subsequent 
deletion study on the new mutant, three more gene deletions predicted a redirect of 
carbon flux to 2-acetolactate production.  Another application of L. lactis has been as 
an oral delivery vehicle for recombinant protein vaccines.  To investigate this, the L. 
lactis GEM was updated to include recombinant protein synthesis reactions and used 
to optimize production of recombinant proteins [21].  Specifically, this study 
optimized production of Green Fluorescent Protein (GFP) (a model heterologous 
protein) using dFBA.  The top performing strain predictions were tested in vivo and 
found to have 15% increased GFP production.  The increase in expression was lower 
than predicted using the GEM, however the qualitative effect was still observed.  
 
Streptococcus thermophilus is commonly used in the production of yogurt and 
cheeses involving high cooking temperatures.  The metabolic GEM enabled the 
comparison of S. thermophilus with L. plantarum and L. lactis metabolism [22].  
Considering its evolution in protein-rich milk environments, S. thermophilus was 
surprisingly found to produce 18 amino acids.  The GEM also identified a unique 
acetaldehyde (yogurt flavor) production pathway.  
 
2.2 Production of Biopolymers 
 
Today, most synthetic materials (e.g., plastics) are produced via petroleum refining.  
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In an effort to reduce dependence on unsustainable processes, alternative production 
routes for plastics are desirable.  For example, poly-3-hydroxyalkanates (PHAs) are 
microbial produced biodegradable polyesters that could potentially replace 
petrochemical-based plastics.   
 
PHA production was investigated using two metabolic GEMs of Pseduomonas 
putida.  The first GEM was used to suggest precursor metabolites and showed that 
select fatty acids and carbohydrates were the best PHA precursors [23].  This was 
expected since carbon sources leading to high levels of acetyl coenzyme A (acetyl-
CoA) are good PHA production candidates.  Soon after the publication of this P. 
putida model, a second metabolic GEM [24], also analyzed to improve PHA 
production, was published.  PHA and biomass (growth) pathways utilize the same 
metabolic precursors, so FBA predicts no PHA production when optimizing for 
growth.  To overcome this, OptKnock was applied to the second GEM to increase the 
pool of the primary precursor acetyl-CoA.  Six mutations were predicted, one of 
which demonstrated a 29% acetyl-CoA increase.   
 
2.3 Production of Biofuels 
 
Biofuels have potential to provide a sustainable and environmentally-friendly fuel 
source.  Metabolic GEMs hold great promise to guide strain design for improved 
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biofuel production by microorganisms [25].  In addition to the model fermentation 
organisms for ethanol, GEMs for lesser-characterized organisms that naturally exhibit 
useful properties are attractive for biofuel production.  Currently, GEMs to improve 
ethanol, butanol, hydrogen and methane production have been developed and studied. 
The hydrogen producing algae Chlamydomonas reinhardtii is discussed in Section 
2.5. 
 
Acetone-butanol-ethanol production 
 
For alcohol production, a global understanding of metabolic behavior is critical.  
Microbe production of alcohols is limited by the toxicity of these compounds at high 
concentration.  Understanding the solution space defined by the metabolic network 
reveals whether the organism has reached its maximum production potential and is 
limited by toxicity (requiring engineering approaches that delve into dynamics and 
regulation). If not, the stoichiometric threshold has not been reached and alcohol 
production can be enhanced by redistributing carbon flux.   
 
The E. coli and S. cerevisiae models have been used to improve ethanol production 
and are discussed in Section 4.  Similarly, Clostridium acetobutylicum – the natural 
acetone-butanol-ethanol production organism that advantageously co-ferments 
pentoses and hexoses – has two GEMs [26, 27] that can be used to increase 
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biobutanol production.  In [26], 207 lethal reactions were found on minimal media, 
140 on partially supplemented medium and 85 on supplemented medium [27] found 
194 essential reactions.    
 
Methanogens 
 
Methanogens anaerobically convert low-carbon substrates to methane, and can 
degrade industrial, agricultural and toxic wastes containing large amounts of organic 
material.  A GEM was reconstructed for Methanosarcina barkeri to study 
methanogenesis, representing the first archaeon GEM [28].  This model led to 55 new 
functional genome annotations, was used to suggest a minimal media, and uncovered 
the stoichiometry of three previously uncharacterized aspects of methane production.   
 
Mutualistic methane production was investigated in the coupled study 
of Desulfovibrio vulgaris and Methanococcus maripaludis metabolic behavior, the 
first demonstration of a flux balance model for a two-organism system [29].  Though 
not genome-scale, it represents an interesting application of traditional constraint-
based analysis.  The two-system model was developed by separately reconstructing 
the central metabolism of D. vulgaris and M. maripaludis, and then integrating the 
networks as a single syntrophic system by compartmentalization.  Unlike in 
eukaryotic models, compartments were separated by the extracellular environment, 
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making transporter existence in both species critical.  From this model, it was 
discovered that formate was not required as an electron shuttle between the 
organisms, but that growth was not possible without hydrogen transfer. 
 
2.4 Applications in bioremediation 
 
Bioremediation takes advantage of a microbe’s ability to reduce and potentially 
eliminate toxic effects of environmental pollutants.  Additionally, microbes capable 
of degrading harmful waste produce useful chemicals as byproducts, and hence are 
intriguing production organisms as well [30].  
 
Acinetobacter baylyi is an innocuous soil bacterium that degrades pollutants and 
produces lipases, proteases, bioemulsifiers, cyanophycine, and biopolymers.  A. 
baylyi is easily transformed and manipulated by homology-directed recombination, 
enabling straightforward metabolic engineering.  Therefore, the GEM is accompanied 
by an extensive library of mutants, and was validated against wildtype growth 
phenotypes in 190 environments and gene essentiality data for nine environments 
[31].   
 
Geobacter metallireducens reduces Fe(III) and is used in bioremediation of uranium, 
plutonium, technetium, and vadium.  Its ability to produce electrically conductive pili 
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makes it useful for harvesting electricity from waste organic matter and as a 
biocatalyst in microbial fuel cell applications.  Using G. metallireducens’ GEM, 
growth on different electron donors and electron acceptors was investigated [32].  
Model analysis revealed energy inefficient reactions in central metabolism, and 
experimental data suggested that the inefficient reactions were inactive during 
biomass optimization on acetate, but up-regulated when grown with complex electron 
donors.  Additionally, the model was tested for flux predictions by comparison with 
13C labeling flux analysis.  Simulations suggested the TCA cycle was used to oxidize 
91.6% of acetate, in agreement with 90.5% in 13C labeling experiments.  
 
Geobacter sulfurreducens has similar industrial applications to G. metallireducens. 
OptKnock was applied to the G. sulfurreducens GEM [33] to improve extracellular 
electron transport [34].  Gene deletions in the fatty and amino acid pathways and in 
central metabolism were predicted to increase respiration and cellular ATP demand.  
To study the ATP demand increase, an ATP drain was added to the GEM.  The model 
showed the rise in ATP usage correlated to decreased biomass flux and increased 
respiration rate.  Experimental results confirmed that an ATP drain demonstrates the 
predicted results.  Increasing electron transfer in G. sulfurreducens has advantages in 
both bioremediation and microbial fuel cell development, though increased fuel cell 
current was not found with this mutant strain.   
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2.5 Photosynthetic Organisms 
 
The sun's energy can be captured either directly by using photosynthetic organisms as 
cell factories, or indirectly through plant biomass.  Photosynthetic organisms can (i) 
remove CO2 from the environment, thereby reducing the impact of global warming; 
(ii) use light to produce carbon-based products; and (iii) create energy gradients.  
While there is one plant GEM available (Nature Precedings [35]), this section will 
focus on photosynthetic microbes.  
 
The algae Chlamydomonas reinhardtii is most commonly utilized for biofuel and 
biohydrogen production.  C. reinhardtii’s GEM was reconstructed using an iterative 
method that integrates experimental transcript verification with computational 
modeling [36].  An initial metabolic network revealed genes needing experimental 
definition and validation, the completion of which refines the model through 
verification of hypothetical transcript existence.  Resulting pathway gaps were filled 
by incorporating alternative enzymes, providing the basis for further transcript 
verification and network modeling.   
 
Halobacterium salinarum is an extreme halophilic archaeon capable of surviving 
with light as its only energy source.  It produces bacteriorhodopsin (a light-driven 
proton pump) – the only known structure with non-chlorophyll based photosynthesis 
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– for use in optical security, optical data storage, and hologram creation.  H. 
salinarum can also store energy (like a battery) using a large potassium gradient.  
Its GEM [37] was used to investigate aerobic essential amino acid degradation, and to 
integratively study energy generation, nutrient utilization, and biomass production.   
 
Cyanobacteria are a subset of prokaryotes that execute oxygenic photosynthesis.  
Synechocystis sp. is a fresh water cyanobacterium for which powerful genetic tools 
are available (e.g., transformation tools, genetic markers).  As a potential biofuel 
production organism, Synechocystis could convert CO2 to carbon-based products.  To 
test this ability, two genes were experimentally transformed into the metabolic 
network of Synechocystis to complete an ethanol-producing pathway.  The CO2 
fixation to pyruvate was diverted to ethanol production – allowing for direct 
conversion of CO2 to ethanol using only light energy.  To investigate the added 
pathway’s systemic effects, the two reactions corresponding to the gene additions 
were added to the GEM [38].  Analysis showed that the mutant strain should also 
now produce succinate and malate, as was subsequently verified experimentally. 
 
3 MEDICAL BIOTECHNOLOGY APPLICATIONS OF GENOME-SCALE IN 
SILICO METABOLIC MODELS  
 
In addition to applications in industrial biotechnology, systems-level metabolic 
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modeling has been widely utilized in medical biotechnology.  To capture the potential 
of constraint-based analysis and further improve drug production and target 
identification, metabolic GEMs spanning a range of diseases have been formulated.  
Demonstrated applications are grouped into three categories: anti-pathogen target 
discovery, drug and nutrient production, and mammalian systems.  
 
3.1 Anti-pathogen Target Discovery   
 
Microbial strains are the causative agents of numerous human diseases.  Pathogen 
GEMs are thus primarily used to identify drug targets that would inhibit cellular 
function.  Importantly, the GEM for humans [39, 40] informs these pathogen studies 
by identifying enzyme targets essential for the pathogen and not for humans.  Most 
modeling studies of pathogens generate sets of essential genes and reactions under 
conditions representing their host environment to identify new antibiotic targets 
(Figure 4).  A smaller number of studies report potential chemical inhibitors of these 
targets, and models have even been used to predict the specific effects of various drug 
compounds on the organism.   
 
Modeling of Staphylococcus aureus, a bacteria infecting multiple regions of the 
body, aims to elucidate the origin of its antibiotic resistance and to identify new drug 
targets.  Its first metabolic GEM was used to identify essential genes and reactions on 
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both rich and minimal media [41].  In this study, the authors generated a literature-
derived list of potential combative drugs (chemical inhibitors corresponding to 
essential reaction targets) for the predicted targets.  A later study identified 
metabolites essential for S. aureus survival [42].  A second GEM was extensively 
validated against experimental data and used to predict 158 lethal intracellular 
reaction knockouts [43].  Five of these knockouts had already been experimentally 
identified as lethal.  Further analysis showed that biosynthesis pathways for glycans 
and lipids were particularly susceptible to deletions, making them interesting for 
antibiotic development.  The most recent S. aureus modeling study combined 
metabolic reconstruction methods with genomic and sequence homology data to build 
a set of models representing the 13 different S. aureus strains [44].  44 genes were 
predicted to be unconditionally essential across all strains.  While a number of the 
essential genes were reported to have roles in fatty acid biosynthesis, the majority of 
the 10 common synthetic-lethal gene pairs identified belong to amino sugar 
biosynthesis pathways.  
 
Respiratory Pathogens  
 
Haemophilus influenzae causes otitis media as well as acute and chronic respiratory 
infections, most often in children.  Even with the H. influenzae type b (Hib) vaccine, 
an estimated 380,000 to 600,000 Hib deaths sill occur world-wide each year.  
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Furthermore, non-typeable H. influenzae strains lacking the vaccine target are 
becoming a major pathogen in both children and adults.  The H. influenzae GEM was 
initially used to identify 11 genes predicted as critical in minimal substrate conditions 
[1].  Interestingly, six of the 11 genes were also determined to be critical in more 
complete substrate conditions reflecting the human host environment of H. 
influenzae.  A later study integrated protein expression data with the model to predict 
essential enzymatic proteins in aerobic and microaerobic conditions [45].   
 
Mycobacterium tuberculosis is a significant cause of human disease in the third 
world, killing over two million people annually.  Two metabolic GEMs for M. 
tuberculosis exist: GSMN-TB [46] and iNJ661 [47].  The GSMN-TB model contains 
five genes encoding enzymes that are known drug targets, all correctly predicted to be 
essential [46].  In a later study, FBA was combined with gene expression data to 
interrogate the metabolic network and predict the effects of different drugs, drug 
combinations, and nutrient conditions on mycolate biosynthesis [48].  Mycolates are 
key components of the mycobacterial cell wall, and mycolate metabolism is a target 
of well-known antituberculosis drugs. A separate study using iNJ661 identified 
mycolate as an essential metabolite [49].  Combined, these results suggest that 
mycolate biosynthesis and degradation pathways are viable targets for new drug 
discovery.  Applying sampling and flux coupling methods to iNJ661, 50 known TB 
drug targets were mapped to hard-coupled reaction (HCR) sets, where a single drug 
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target knocks out an entire set’s functionality [47].  Terminating the activity of other 
enzymes in an HCR theoretically has the same effect, suggesting novel targets.  Most 
recently, gene and reaction essentiality results obtained from both GEMs were 
integrated into a larger in silico target identification pipeline for M. tuberculosis that 
incorporates protein-protein interaction network analysis, experimentally derived 
essentiality data, sequence analyses, and structural assessment of targetability [50].  
 
Another important respiratory pathogen studied through genome-scale modeling is 
Pseudomonas aeruginosa.  The ability of P. aeruginosa to form biofilms in low 
oxygen environments allows it to chronically infect the lungs of cystic fibrosis 
patients.  P. aeruginosa is also responsible for nosocomial infections and acute 
infections in immunocompromised patients.  In silico gene deletions performed with 
its metabolic GEM showed strong agreement with published knockout data [51]. 
 
Gastrointestinal Pathogens  
 
Helicobacter pylori targets the gastric mucosa, leading to diseases such as gastritis, 
peptic ulceration and gastric cancer.  Seven essential genes were predicted in the 
initial H. pylori GEM under four test conditions, representing varying aerobic levels 
and nutrient availability [52].  Importantly, the overall variation between conditions 
revealed that gene essentiality is dependent on the in silico environment.  Using an 
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updated H. pylori GEM, a later study identified 128 essential genes, and the results 
were validated using published experimental data [53].  Most essential genes 
predicted belonged to either the cell wall or vitamin and cofactor subsystems.  In a 
study predicting essential metabolites for cell growth [42], meso-2,6-
diaminoheptanedioate was confirmed as a potential target, while ADP-d-glycero-d-
manno-heptose was identified as a potentially novel target. 
 
Salmonella typhimurium is a source of human gastroenteritis and causes systemic 
infection in mice studied as a model for human typhoid fever.  A variation of the 
typical target-prediction approach identified potential strategies for vaccine 
development [54].  Specifically, gene expression data was used to infer the host 
environmental conditions to which S. typhimurium might be exposed during 
infection.  Model simulations predicted genes essential for intracellular survival, 
providing potential targets for generating avirulent attenuated strains for vaccines.  A 
second S. typhimurium GEM showed good agreement between simulation and 
experimental results for growth patterns under different substrate conditions [55].  
 
Pathogens Infecting Other Systems  
 
Neisseria meningitidis causes meningitis and meningococcal septicemia, and is 
classified into serogroups (groups containing a common antigen) A, B and C.  
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Serogroup B is common in developed countries and has no vaccine.  The membrane 
protein PorA has been identified as a major inducer of, and target for, bactericidal 
antibodies.  As genetically engineered strains expressing more than one PorA subtype 
are now being produced, GEMs can aid in process development of the cultivation 
step.  The metabolic GEM was therefore used to define a minimal medium for N. 
meningitidis growth (successfully tested in batch and chemostat cultures) [56].  
 
Yersinia pestis  infects the lymphatic system and causes bubonic plague, a disease 
without a vaccine that still affects thousands of people annually.  The metabolic GEM 
was used to identify 74 lethal gene deletions and 39 synthetic lethals [57].  Similarly, 
in silico gene deletion studies on the Leishmania major GEM [58], the first GEM for 
a protozoan, revealed multiple essential genes (e.g., trypanothione reductase encoding 
genes) that are absent in humans. L. major is the causative agent of cutaneous 
leishmaniasis in mammalian hosts and is similar to other Leishmania species causing 
diffuse cutaneous, mucocutaneous and visceral forms of the disease.   
 
Mycoplasma genitalium is the closest known representation of the minimal gene set 
required for bacterial growth.  Additionally, M. genitalium is sexually transmitted and 
causes nongonococcal urethritis in men, genital tract inflammatory diseases in 
women, and is thought to increase the risk of HIV-1 contraction.  Presently, model 
predictions have helped to identify minimal media growth components [59].   
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Human oral pathogens such as Porphyromonas gingivalis are the leading cause of 
carious and periodontal disease.  Lipopolysaccharides (LPS) present in the bacterial 
outer membrane trigger the human immune system.  The P. gingivalis GEM 
identified several gene deletions preventing LPS production [60].  One predicted 
strain was confirmed to suffer negative effects, though it was still viable.  Blocking 
LPS production would allow for control of the negative inflammatory responses. 
 
3.2 Production of Drugs and Nutrients  
 
Of interest, some microbial organisms produce antibiotics and other compounds 
conveying health benefits to humans (e.g., vitamins).  Analysis of metabolic GEMs 
for both traditional and novel drug production microorganisms serves to improve 
production efficiency and assist in identifying new drug production routes.   
 
Nutrients & Dietary Supplements  
 
Corynebacterium glutamicum is used industrially to produce amino acids, 
particularly L-lysine and L-glutamate, and can produce ethanol and organic acids 
under oxygen deprivation conditions.  The first metabolic GEM assisted in prediction 
of targets for improved lysine production, showing that lysine production via direct 
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dehydrogenase gives a higher product yield [61].  Soon after publication of the first 
GEM, a second metabolic GEM was published and used to find candidate gene 
deletions to increase organic acid production under oxygen deprived conditions [62].  
Improving lactate production required interruption of succinate-producing reactions.  
Disruption of oxidative phosphorylation reactions also predicted improved production 
of lactate because NADH oxidation demand increased.  Finally, reactions in the 
pentose phosphate pathway were predicted to increase lactate production because an 
alternative reaction was needed to produce NADPH (malate to pyruvate) and the 
increase in pyruvate was converted to lactate.  Succinate production was also 
predicted to be improved by interrupting the lactate producing reactions.   
 
Pharmaceuticals  
 
Aside from E. coli, Bacillus subtilis is one of the best-characterized prokaryotes.  Its 
ability to produce antibiotics, high quality enzymes and proteins, nucleosides, and 
vitamins makes it an important industrial organism.  Two genome-scale metabolic 
models have been created, the second of which used the SEED annotation [63, 64].  
Analysis showed that 79% of the reactions from the earlier model were present in the 
later model, with 64% agreement in gene-reaction mapping.  The newer model 
contains a larger number of reactions due to improved annotation and more detailed 
characterization of biomass composition.   
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Streptomyces coelicolor also produces antibiotics, as well as secondary metabolites 
such as immunosuppressants and anti-cancer agents.  It has been demonstrated 
experimentally that increasing the supply of primary metabolites (those directly 
involved in cell function and growth) – via decreased flux through primary metabolic 
pathways – leads to increased secondary metabolite production in various 
Streptomyces strains.  The S. coelicolor GEM [65] was used to study the effect of 
reduced phosphofructokinase (PFK) activity on increasing secondary metabolite 
production [66].  The model subset used showed that applying constraints to limit 
secretion of other secondary metabolites (acetate, acetaldehyde, ethanol, formate, and 
proline) did not increase antibiotic production when PFK activity was reduced.  The 
predicted decrease in specific growth rate and increase in pentose phosphate pathway 
flux was observed experimentally.  Another study applied flux variability analysis to 
the original metabolic GEM to investigate the effects of different culture feed 
conditions on glucose assimilation and antibiotic production [67].   
 
3.3 Mammalian Systems 
 
Metabolism is a critical aspect of human physiology, and metabolic malfunction is a 
major contributing factor in many human diseases.  Metabolic modeling of 
mammalian cells can be used to study tissue specific function [68] and human disease 
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[69, 70].  Mammalian cell cultures (non-human) can also be used in the production of 
biopharmaceuticals such as monoclonal antibodies and vaccines [71].   
 
The recent completion of a global reconstruction of the metabolic network in Homo 
sapiens [39, 40] represents a significant milestone in human systems biology.  In 
addition to the typical network capabilities determined by constraint-based modeling, 
Human Recon 1 has enabled analysis of relationships between network topology and 
human metabolic diseases [69].  In a more specific example, a novel computational 
approach was applied to the GEM to identify biomarkers for inborn errors of 
metabolism [70].  This method revealed a set of 233 metabolites whose concentration 
is predicted to increase or decrease as a result of 176 possible dysfunctional enzymes.  
Human Recon 1 has also been used to explore tissue-specific metabolism across a 
number of major organ systems. The model was combined with tissue-specific gene 
expression data to predict tissue-specific activity of metabolic-disease genes and 
secreted metabolites [68].  An independently reconstructed human 
GEM [40] revealed the potential of systems modeling in human metabolism to aid in 
drug discovery [72].  Recently, efforts have focused on reconciling these 
reconstructions. 
Mus musculus, the common laboratory mouse, has been found to have 99% 
similarity with the human genes in coding regions [73].  With extensive experimental 
data available, the mouse provides a terrific model organism for studying genetic 
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systems of relevance to humans.  The M. musculus metabolic GEM was used to 
simulate hybridoma cell line production of monoclonal antibodies (mAbs), and 
results were compared to cell culture data [74].  The model successfully predicted 
growth and production of lactate and ammonia, known byproducts of mammalian cell 
cultures that cause cell death and inhibit mAb synthesis.  However, the model did not 
predict the production of a third commonly-observed byproduct, alanine, and did not 
explain the high production of lactate, ammonia, and alanine in animal cells.  In 2009, 
an updated GEM was the subject of in silico analysis to identify strategies for 
optimizing cell density and mAb production in hybridoma cultures [75].  This GEM 
produced all expected amino acids.  Based on cell culture measurements under 
various nutrient conditions and model simulations of internal metabolic states, 
potential feed-media conditions for enhancing cell density and mAb production were 
suggested. 
 
4 GENOME-SCALE IN SILICO METABOLIC MODELS WITH 
APPLICATIONS IN BOTH INDUSTRIAL AND MEDICAL 
BIOTECHNOLOGY 
 
4.1 Mannheimia succiniciproducens for succinate production 
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Succinate has importance in the food, agricultural, chemical, and pharmaceutical 
industries, and can be used in the synthesis of biodegradable polymers and green 
solvents.  Currently, succinate is produced industrially from liquid petroleum gas via 
a chemical process.  
 
To optimize microbial succinate production, a GEM was constructed 
for Mannheimia succiniciproducens [76].  Simulations of three mutant strains 
designed to increase succinate production were conducted.  Good agreement was 
found between the experimental and in silico predictions for growth rate, and for 
succinate and acetate production by one strain.  The prediction for formate was not in 
such good agreement, but the model accurately predicted that lactate, pyruvate and 
malate would not be produced.  The flux simulation agreed with experiments in its 
prediction of the route to succinate.  Two of the three mutants were more complex 
and results were initially not in agreement with experiment, but were similar after 
applying additional constraints to the model for one of the complex strains.  The best 
succinate producing strains found using FBA yielded 92.59% of the maximum 
possible succinate production with only 25.50% reduction in growth rate.  Constraint-
based analysis on the model was later used to identify an ideal operating range of 
CO2 to maximize cell growth rate and succinate production for a given glucose 
uptake rate [49].   
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4.2 E. coli 
 
E. coli and S. cerevisiae (Section 4.3) are two of the best studied microbial species to 
date [77, 78], and serve as critically important organisms from which much about 
biology has been learned. The E. coli  metabolic GEM has been extensively used in a 
wide spectrum of applications, including increased production of lycopene [79, 80], 
succinate [16, 81, 82], lactate [16, 83], malate [84], L-valine [85], L-threonine [86], 
additional amino acids [87], ethanol [88], hydrogen [17, 89], vanillin [17], and 1,3-
propanediol (PDO) [16].  As one of the earliest GEMs and most extensively 
experimentally studied microorganisms, the E. coli model has been updated multiple 
times [90-92]. 
 
Quadruple gene deletions proposed by OptKnock were tested experimentally and 
resulted in a strain capable of increased lactate production (0.87-1.75 g/L per 2 g/L 
glucose) [83].  Adaptive evolution experiments on the engineered strains showed 
coupling of lactate production and growth, and the new strains increased lactate 
secretion rates.  Constraint-based analysis of the E. coli GEM also guided strain 
design for increased production of the food additive malate, predicting the addition of 
a M. succiniciproducens reaction [84].  In another food engineering study, OptStrain 
identified three reactions to be introduced into E. coli for vanillin production [17].  
OptKnock was then used to systematically search for gene deletions to enhance 
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vanillin yield.  For biofuels, an algorithm called OptReg [88] examined the effects of 
up-regulation of genes and to those of down-regulation and gene knock-outs to 
identify genes capable of enhancing ethanol production. With a focus on health 
applications, a MOMA-based procedure was used to sequentially examine and select 
sets of multiple gene deletions enabling optimal yields of the antioxidant lycopene, 
while still maintaining sufficient growth rates [79].  In another study, comparative 
genome analysis of E. coli and M. succiniciproducens was performed to predict five 
candidate genes to overproduce succinate in E. coli [81, 82].  
    
A combination of strategies was used to develop an enhanced L-valine producing E. 
coli strain [85].  First, an L-valine producing strain was constructed by removing 
known feedback inhibition mechanisms and attenuation controls, and amplifying L-
valine biosynthetic enzymes activity.  This strain was improved in a stepwise manner 
using information derived from transcriptome profiling (i.e., the identification of a 
global regulator and exporter of L-valine).  MOMA was applied to identify triple-
knockout targets.  The effect of the triple-knockout mutation was more drastic with 
respect to L-valine production in a strain overexpressing the global regulator gene and 
the exporter encoding gene than in a strain without these overexpressed genes.  
Analysis was also performed to uncover amplification targets for improved L-
threonine production [86].  The strain was engineered to reduce byproduct 
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accumulation during fed-batch culture by diverting the flux to L-threonine through 
overexpression of another GEM-identified gene. 
   
Due to the inherent robustness of E. coli metabolism, only a subset of the metabolic 
genes was known to be lethal in single-gene deletion experiments [93].  Alternative 
approaches addressed this limitation by identifying synthetic lethals, or even higher-
order lethal sets.  These efforts dramatically expanded the range of knockout 
candidates.  These lethal multiple-gene knockouts were identified in silico [42, 94-
96], and antibacterial targets found through metabolite essentiality analyses [95] have 
been further explored [42]. 
  
4.3 S. cerevisiae 
 
The yeast S. cerevisiae is one of the most widely studied model organisms for 
eukaryotes; research detailing its genetics, biochemistry, and physiology has provided 
a wealth of insight into mechanisms and behavior in higher-level organisms.  S. 
cerevisiae is also capable of large-scale fermentation for the production of fuels, 
chemicals, pharmaceuticals, materials, nutritional compounds, and food ingredients.  
 
The first S. cerevisiae GEM [97] was later expanded to establish a fully 
compartmentalized metabolic GEM [98], which was later updated [99].  An 
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independently constructed GEM features a more detailed description of a lipid 
metabolism [100].  To reconcile the information in different models, a consensus 
GEM based on community knowledge has been collaboratively reconstructed, though 
this network reconstruction still lacks a biomass equation [101]. 
   
Ethanol is the predominant product in anaerobic fermentations with S. cerevisiae.  
With the availability of metabolic GEMs, constraint-based analyses can now be 
applied in new ways to systematically identify genetic engineering routes to increase 
ethanol production.  For example, simulations predicted an insertion of the gapn gene 
as a strategy that could increase the ethanol yield, both with glucose as the sole 
carbon source as well as with a mixture of glucose and xylose, and experiments 
successfully validated this prediction [102].  Employing dFBA, another study 
demonstrated that the degree of compartmentalization in GEMs can impact the 
predicted mutant phenotypes [103]. 
   
Also in yeast, OptGene (an improvement of OptKnock) was used to identify potential 
metabolic engineering targets for increased production of succinate, glycerol, 
vanillin, and sesquiterpene [104, 105].  Growth phenotype predictions made using the 
S. cerevisiae GEM with simulated single-gene knockouts were consistent with 
experimental observations [106].  The phenotypic effects of multiple gene knockouts 
in the context of biological robustness and epistasis were also explored [107, 108].  
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As discussed in [109], such gene knockout studies can assist antimicrobial target 
discovery. 
  
4.4 Aspergillus 
 
Aspergillus is a filamentous fungus important to the medical and biotechnological 
(industrial and agricultural) communities.  Aspergillus produces mycotoxins capable 
of contaminating crops, and can cause disease in immuno-compromised animals and 
humans.  More constructively, Aspergillus are used in the production of bulk 
chemicals, enzymes, and pharmaceuticals.  These applications have made Aspergillus 
a popular fungal species in research.   
 
Aspergillus niger is an industrial workhorse used to produce high yield products 
ranging from citrates and gluconates to important enzymes and proteins (e.g., human 
interferon).  The A. niger metabolic GEM  [110] was used to identify a gene deletion 
pair predicted to increase succinate production [111].  This mutant was tested 
experimentally, and as predicted, a significant increase in succinate production was 
observed when grown on both glucose and xylose.  Unexpectedly, an increase in 
fumarate was seen when grown on xylose (though not when grown on glucose), 
suggesting that A. niger uses either the oxidative TCA cycle or the glyoxylate shunt 
for succinate production.  A. niger  converts up to 95% of the available carbon to 
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organic acid, and, if unbuffered, can rapidly drop the pH to below 2.  It has been 
found experimentally that depending on the ambient pH, A. niger produces a different 
organic acid.  To study this process, the GEM was expanded to include information 
relating to the number of protons released for one mole of each acid.  Using this 
GEM, the optimal strategy for acidifying the surrounding environment can be found 
computationally.  The pH levels for citrate and oxalate were reproduced, verifying in 
silico the hypothesis that A. niger produces these to acidify its surrounding 
environment [112].  Other Aspergillus metabolic reconstructions include Aspergillus 
nidulans and Aspergillus oryzae (Table 1).  A. nidulans  [113] is a model organism 
for studying cell development and gene regulation, and A. oryzae [114] has 
historically been used to produce soy sauce, miso and sake.  A. oryzae is also used for 
the production of fungal enzymes such as alpha-amylase, glucoamylase, lipase and 
protease.   
 
4.5 Host-Symbiote Relationships 
 
The GEM-based study of host-symbiote relationships can shed light on the shared 
behavior and provide insight into industrial production abilities of the symbiote.  
Host-symbiote relationships have two primary modes of computational investigation: 
GEMs can be reconstructed for each participant and analyzed alone, or they can be 
constructed as an integrated network (see methanogens section). Obligate symbiotes 
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in particular benefit from genome-scale in silico analysis as they cannot be cultured – 
and thus experimental results cannot be readily obtained. 
 
Buchnera aphidicola is an endosymbiote of the pea aphid whose metabolic GEM has 
been constructed to investigate symbiote-host interaction [115].  Interestingly, it was 
found that the B. aphidicola genome is essentially a subset of the E. coli genome 
[116].  Not surprisingly, a large percentage of genes from this network were predicted 
to be required for growth (84% by FBA and 95% by MOMA), showing that this 
organism’s metabolic network is much less robust and complex than most.  The 
bacterium cannot grow without secreting the essential amino acid, histidine, for use 
by its host.  Further, the amount of essential amino acid produced by the bacterium in 
silico can be controlled by host supply of carbon and nitrogen substrates – possibly 
explaining the regulation of amino acid output to the host. 
 
Another symbiotic bacterium, Rhizobium etli, fixes atmospheric nitrogen into 
ammonium.  A metabolic GEM for R. etli is of interest for plant development and in 
agriculture.  R. etli obtains carbon sources from the plant and in turn provides 
ammonium, alanine and aspartate.  Instead of using a biomass objective in its 
metabolic GEM [117], an objective function was formulated containing all 
compounds needed for symbiotic nitrogen fixation.  This was done because the 
nitrogen fixation phase of the organism's life is of most interest, and in this phase 
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does not grow.  A double gene deletion was identified with a predicted increase in 
nitrogen fixation. 
 
5 GENOME-SCALE IN SILICO REGULATORY MODELS 
 
While genome-scale metabolic modeling strategies can be powerful, they are not 
completely predictive.  In addition to incomplete or incorrect aspects of the 
reconstructions, one reason for failed predictions results from the lack of metabolite-
level or transcriptional regulation of metabolism.  Constraint-based analysis of 
metabolic GEMs typically assumes all metabolic enzymes are transcribed and 
available under all conditions, which is rarely the case.  Thus, there is a compelling 
need to use procedures that incorporate metabolic regulation.  Specifically, metabolic 
regulation can be categorized into two groups: transcriptional regulation that controls 
enzyme expression and metabolite-level regulation (e.g., allosteric regulation).  
Figure 5 illustrates the interplay between both regulation types, such as when 
transcriptional regulation is itself affected by metabolite concentrations (e.g., 
feedback/feedforward inhibition/activation).   
 
TRNs enhance metabolic simulations by providing information about 
transcriptionally active enzymes under different conditions.  Recent efforts have 
attempted to reconstruct integrated networks, comprising both metabolic reactions 
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and the regulatory rules that govern metabolic phenotypes, in order to more 
accurately represent metabolic phenotypes.  One method linking the transcriptional 
state of an organism with metabolism is rFBA [3, 6].  rFBA uses Boolean rules to set 
gene activity for an enzyme as either ON or OFF based on the state of transcription 
factors and the environment.   
 
The first integrated metabolic-regulatory network at the genome scale was 
reconstructed for E. coli [4].  This integrated model included 1,010 genes: 906 from 
the metabolic network [91], and 104 regulatory genes, whose products (i.e., 
transcription factors) together with other stimuli control the expression of 479 of the 
906 metabolic enzymes and transports.  The model predicted the outcomes of gene 
expression and growth phenotyping experiments, revealed knowledge gaps, and 
enabled the identification of additional components and interactions in each network.  
Steady-state regulatory FBA (SR-FBA), which reformulated rFBA using mixed 
integer linear programming [118], was later used to search the multiple solutions of 
rFBA rather than obtain only a particular flux state as with the Boolean-logic 
updating method for rFBA.  More recently, a matrix formalism [119] was applied to 
the most updated integrated metabolic-regulatory model: among the 1260 genes in 
the metabolic model [92], 503 gene targets were regulated by the expression state of 
125 transcription factors [120].  In addition to computing the transcription state of the 
genome, this formalism was used to describe intrinsic properties of the transcriptional 
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regulatory states which could be analyzed by methods such as Monte Carlo sampling 
across a subset of all possible environments. 
 
The first large-scale integrated metabolic-regulatory model in a eukaryotic organism 
was constructed for S. cerevisiae [6], containing 55 nutrient-regulated transcription 
factors that control a subset of the 750 genes in the metabolic network [98].  The 
rFBA approach [3] predicted gene expression changes and growth phenotypes of 
gene knockout strains.   
 
 
6 CONCLUSIONS 
 
We present an extensive review of the biotechnology applications of genome-scale 
modeling efforts to date, demonstrating the vast array of organisms already available 
for model-guided strain design and investigation of biochemical behavior.  With the 
rise in high-throughput measurement technologies and the growing number of 
sequenced genomes, the continued construction of in silico GEMs will provide 
increasingly powerful tools to investigate biological systems.  While existing models 
and corresponding analysis techniques have been developed primarily for 
metabolism, transcriptional regulation and transcription-translation processes are 
emerging.  Many of the studies highlighted herein reveal the utility of GEMs for 
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generating predictions for experimental testing and design, as well as providing 
valuable insight into metabolic function.  Commonly, in silico simulations are 
employed to study the effects of genetic perturbations on the stoichiometric abilities 
of a cell.  In this way, these studies have used GEMs to predict engineering strategies 
to enhance properties of interest in an organism and/or inhibit harmful mechanisms of 
pathogens or in disease.    
 
Looking forward, technology and computational method development will 
continuecontinues to improve the predictive capability and usefulness of in silico 
GEMs.  These efforts focus on “integration,” whether in regard to heterogeneous 
high-throughput data types, or different scales and scopes of biological processes.  As 
technological advances enable increasingly comprehensive and accurate 
measurements of intracellular and extracellular metabolite concentrations [121], these 
data will greatly inform GEM reconstruction and analysis, including for dynamics. 
Integration of cellular regulation and signaling with metabolic information is 
important for predicting diverse network states. The successes with the genome-scale 
TRN in E. coli [4, 5, 120] and S. cerevisiae [6] demonstrate the potential of metabolic 
networks controlled by gene expression.  Similarly, the recent invention of a genome-
scale transcriptional-translational network model (demonstrated in E. coli [7]) will 
allow for integrated analysis of transcriptomic and metabolic states.  Contrary to 
these successes though, analysis of allosteric regulation between metabolites and 
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enzymes is still lacking in GEMS because of sparse high-throughput data and 
applicable computational methods to uncover these genome-scale relationships.  
Similar technical problems exist for intracellular signaling networks as GEMs, 
although integration of metabolic, transcriptional regulatory, and signaling networks 
has been investigated [5, 122].  As network integration becomes commonplace, 
consistent formatting and naming conventions must become a priority to assist in 
seamless melding of information. Achieving integration of the different biochemical 
processes will open another avenue to ultimately realize whole-cell simulation. 
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TABLES 
 
Table 1. Genome-scale metabolic models to date.  Under “Domain”, bacteria, 
eukaryote, and archaea are marked as “b”, “e”, and “a”, respectively. 
 
Organism Domain 
Model Details 
# rxns / # mets / # genes 
Refs Demonstrated/Intended Applications 
Lactobacillus plantarum b 643 / 531 / 721 [19] lactate [123] 
Lactococcus lactis b 621 / 422 / 358 [20] lactate [20], diacetyl [20] 
Streptococcus thermophilus b 522 / --- / 429 [22] lactate, acetaldehyde 
Pseudomonas putida b 
 
950 / 911 / 746 [23] polyhydroxyalkanoates [23, 24], 
bioremediation, biocatalytic chemicals, 
improvement of fossil fuel quality, 
promoting plant growth, pest control 
Pseudomonas putida 877 / 886 / 815 [24] 
Clostridium acetobutylicum b 502 / 479 / 432 [27] acetone, butanol, ethanol, hydrogen 
Clostridium acetobutylicum 552 / 422 / 474 [26] 
Methanosarcina barkeri a 509 / 558 / 692 [28] methane 
Desulfovibrio vulgaris b --- / --- / --- [29] methane 
Methanococcus maripaludis a --- / --- / --- [29] methane 
Acinetobacter baylyi b 875 / 701 / 774 [31] pollutant degradation, lipases, proteases, 
bioemulsifiers, cyanophycine, various 
biopolymers 
Geobacter metallireducens b 697 / 769 / 747 [32] reducing Fe(III), bioremediation of 
uranium, plutonium, technetium & vadium, 
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fuel cell development 
Geobacter sulfurreducens b 523 / 541 / 588 [33] reducing Fe(III), bioremediation of 
uranium, plutonium, technetium & vadium 
[34], fuel cell development [34] 
Arabidopsis thaliana  e --- / --- / --- [35] photosynthetic plant cell, various 
secondary metabolites, flavonoid, 
polyamine metabolism 
Chlamydomonas reinhardtii  e 259 / 113 / 174 [36] photosynthetic green algae, hydrogen 
production 
Halobacterium salinarum a 711 / 557 / 490 [37] producing bacteriorhodopsin  
Synechocystis sp b 831 / 704 / 633 [38] photosynthetic cyanobateria, ethanol 
production [38] 
Staphylococcus aureus b 640 / 571 / 691 [41] antibiotic target [41-44] 
Staphylococcus aureus 774 / 712 / 551 [43] 
Staphylococcus aureus  
 (multiple strains) 
1444~97 / 1399~1437 / 522~47 [44] 
Haemophilus influenzae b 461 / 451 / 412 [1] antibiotic target [1, 45] 
Pseudomonas aeruginosa b 883 / 760 / 1056 [51] antibiotic target [51] 
Mycobacterium tuberculosis b 849 / 739 / 726 [46] antibiotic target [42, 46-48, 50] 
Mycobacterium tuberculosis 939 / 828 / 661 [47] 
Helicobacter pylori b 476 / 485 / 341 [53] antibiotic target [42, 53] 
Salmonella typhimurium b 1087 / 744 / 1038 [54] antibiotic target [54] 
Salmonella typhimurium 1964 / 1036 / 945  
Neisseria meningitidis b 496 / 471 / 555 [56] vaccine development, antibiotic target 
60 
 
Yersinia pestis  b 1020 / 825 / 818 [57] vaccine development, antibiotic target 
Leishmania major e 1112 / 1101 / 560 [58] antibiotic target [58] 
Mycoplasma genitalium b 262 / 274 / 189 [59] antibiotic target [59] 
Porphyromonas gingivalis b 679 / 564 / --- [60] control of negative inflammatory responses 
[60] 
Corynebacterium glutamicum  b 446 / 411 / 446 [61] lactic and succinate [62], L-lysine [61], 
glutamate, ethanol 
Corynebacterium glutamicum  502 / 423 / 277 [62] 
Bacillus subtilis b 1437 / 1138 / 1103 [64] antibiotics, industrial enzymes and 
proteins, nucleosides and vitamins 
Streptomyces coelicolor b 971 / 500 / 711 [65] secondary metabolites (antibiotics, 
immunosuppressants, anti-cancer agents) 
[66, 67] 
Homo sapiens e 3311 / 2766 / 1496 [39] biomarker of inborn error [70], 
understanding disease comorbidity toward 
diagnosis and prevention [69], 
identification of mutations causing defects 
in Leigh’s cells [124], predicting tissue-
specific activity of metabolic genes [68] 
Homo sapiens 2823 / 2671 / 2322 [40] 
Mus musculus e 1344 / 1042 / --- [75] mouse hybridoma cells for enhanced 
production of monoclonal antibodies [75] 
Mannheimia succiniciproducens b 686 / 519 / 425 [76] succinate [76] 
Escherichia coli b 2077 / 1039 / 1260 [92] lycopene [79, 80], succinate [16, 81, 82], 
lactate [16, 83], malate [84], L-valine [85], 
L-threonine [86], additional amino acids 
[87], ethanol [88], hydrogen [17, 89], 
vanillin [17], 1,3-propanediol (PDO) [16], 
gene KO [94-96], antibacterial target [42] 
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Saccharomyces cerevisiae 
 (fully-compartmentalized) 
e 1412 / 1228 / 904 [99] ethanol [102, 103], succinate [104], 
glycerol [104], vanillin [104], 
sesquiterpene [105], gene KO [106-108] 
Saccharomyces cerevisiae
 (lipids emphasized) 
1446 / 1013 / 800 [100] 
Saccharomyces cerevisiae
 (consensus model) 
1857 / 1168 / 832 [101] 
Aspergillus niger e 1197 / 1045 / 871 [112] succinate [111], citrates and oxalates [112], 
additional organic acids, industrial 
enzymes, proteins (chymosin, human 
interferon) 
Aspergillus nidulans e 676 / 733 / 666 [113] model organism for studies of development 
biology & gene regulation, sharing many 
applicative properties of A. niger 
Aspergillus oryzae e 1053 / 1073 / 1314 [114] fermented sauces, industrial enzymes 
Buchnera aphidicola b 263 / 240 / 196 [115] symbiotes producing histidine [115] 
Rhizobium etli b 387 / 371 / 363 [117] symbiotic nitrogen fixation [117] 
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FIGURE LEGENDS 
 
Figure 1. Completed genome sequences and genome-scale models (GEMs) available 
to date. 
 
Figure 2. Applications of GEMs in industrial and medical biotechnology. 
 
Figure 3. Iterative process of model generation, hypothesis formation, and model 
refinement to guide strain design for enhanced microbial production. 
 
Figure 4. Iterative modeling of pathogens to identify new antibiotic targets and 
therapeutic strategies. 
 
Figure 5. Overview of key processes governing the interplay between metabolic and 
transcriptional regulatory networks, demonstrating the utility of integrated modeling. 
 
 
 
  
 





